Initiate coverage on Novavax with a Buy rating; Q1 2025 marks an inflection point with $519M net income and raised revenue guidance to $975M-$1.025B. Novavax's Q1 2025 revenue surged to $667M, driven by $603M from terminated APA agreements and $19M from new vaccine shipments, indicating strong demand. Sanofi partnership converts lower-margin product revenue to higher-margin income, allowing Novavax to focus on R&D and achieve non-GAAP profitability by 2027.

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com

REITs, MLPs, and BDCs are some of the very best places to look for big and predictable dividends. I compare them side by side and share which I think is the best buy of the three today. I also share some of my top picks of the moment.

Harvard Bioscience, Inc. (NASDAQ:HBIO ) Q1 2025 Earnings Conference Call May 12, 2025 8:00 AM ET Company Participants Kathryn Flynn - Corporate Controller Jim Green - Chairman, President & CEO Mark Frost - Interim CFO Conference Call Participants Paul Knight - KeyBanc Bruce Jackson - The Benchmark Company Operator Good day, and welcome to the First Quarter 2025 Harvard Bioscience Inc Earnings Conference Call. All participants will be in a listen-only mode.

Trump's supportive stance on crypto, easing regulatory control, international expansion and a compelling portfolio position COIN for growth.

U.S. auto safety investigators asked Tesla to answer questions on the automaker's plans to launch a paid robotaxi service in Austin, Texas, in June to assess how it will perform in poor weather.

VanEck IG Floating Rate ETF is a fund focused on investment-grade floating rate notes; the latest drawdowns were minimal, helping to highlight its relatively lower volatility. FLTR could be a lower-risk alternative to FINS that we covered recently, avoiding leverage and the added volatility of CEF discount/premiums. FLTR's portfolio is highly diversified and tilted towards investment-grade financial sector holdings, helping to produce minimal losses but carries a reasonable yield.

DLR to gain from its global footprint of data centers with growing digital transformation, cloud computing and the proliferation of AI.

Regeneron Pharmaceuticals gets a buy rating today, agreeing with the Wall St consensus. Impressive are its drug discovery pipeline across several clinical segments, profit margins, and low Debt/Equity ratio. The firm just started paying dividends in February, so still lacks dividend growth data long-term.

Transaction in Own Shares 12 May, 2025 • • • • • • • • • • • • • • • • Shell plc (the ‘Company') announces that on 12 May, 2025 it purchased the following number of Shares for cancellation. Aggregated information on Shares purchased according to trading venue: Date of purchase Number of Shares purchased Highest price paid Lowest price paid Volume weighted average price paid per share Venue Currency 12/05/2025 478,357 £25.2650 £24.9300 £25.0886 LSE GBP 12/05/2025 149,113 £25.2500 £24.9900 £25.0825 Chi-X (CXE) GBP 12/05/2025 92,530 £25.2250 £24.9800 £25.0825 BATS (BXE) GBP 12/05/2025 310,529 €30.1100 €29.7700 …

WESTMINSTER, Colo. , May 12, 2025 /PRNewswire/ -- Ball Corporation ("Ball") (NYSE: BALL) announced today that it priced an underwritten public offering of €850 million aggregate principal amount of 4.250% Senior Notes due 2032 (the "Notes").

Upland Software, Inc. (NASDAQ:UPLD ) Q1 2025 Earnings Conference Call May 12, 2025 11:00 AM ET Company Participants Jack McDonald - Chairman & CEO Mike Hill - CFO Conference Call Participants Ian Black - Needham Company DJ Hynes - Canaccord Jeff Van Rhee - Craig-Hallum Operator Thank you for standing by, and welcome to the Upland Software First Quarter 2025 Earnings Call. At this time, all participants are in listen-only mode.

Even with President Trump reaching a breakthrough trade deal with China, many companies haven't been able to avoid the sting of tariffs. One of the industries that has the most focus is automakers.

Ethereum surges more than 40% in just a week after the Pectra network upgrade. Investors can ride the rally with these ETFs.

@ProsperTradingAcademy's Mike Shorr says the U.S. and China tariff pause was "too easy." He's watching for a potential stock pullback on any negative headlines following the announcement.

President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach.

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Ultra Clean Holdings, Inc. (NASDAQ:UCTT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ultra-clean-holdings-inc-lawsuit-submission-form?prid=148112&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Fluence Energy, Inc. (NASDAQ:FLNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/fluence-energy-lawsuit-submission-form?prid=148108&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your TFI International Inc. (NYSE:TFII) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/tfi-international-inc-lawsuit-submission-form?prid=148109&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 12, 2025 / If you suffered a loss on your Ibotta, Inc. (NYSE:IBTA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ibotta-lawsuit-submission-form?prid=148107&wire=1 or contact Joseph E. Levi, Esq.